8-K: Longevity Health Holdings Secures Up to $625K in Convertible Notes

Longevity Health Holdings announced a new securities purchase agreement with Puritan Partners LLC, securing up to $625,000 in gross proceeds through convertible notes.

Summary

• Longevity Health Holdings entered into a Securities Purchase Agreement with Puritan Partners LLC on August 31, 2026.
• The agreement allows for the issuance of up to $694,445 in aggregate principal amount of 10% senior secured convertible notes.
• The Company expects to receive gross proceeds of up to $625,000 from these notes.
• An initial tranche of $375,000 was received on August 31, 2026, through the issuance of a note with a principal amount of $416,667.
• This initial note bears 10% annual interest and is convertible into common stock at $0.50 per share.
• The notes are secured by substantially all of the Company's and its subsidiaries' assets.
• Additional tranches are contingent on a resale registration statement and Puritan Partners' discretion.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to the reliance on convertible debt with significant dilution potential and asset-backed security, indicating financial strain.

Positives

• Secured additional financing to support business operations and strategic opportunities.
• The CEO expressed satisfaction with deepening the relationship with Puritan Partners, highlighting financial flexibility.

Negatives

• The financing is structured as convertible debt, which can lead to significant dilution for existing shareholders.
• The notes are senior secured, meaning they are backed by substantially all of the Company's assets, potentially impacting other creditors.
• The issuance involves an original issue discount, reducing the net proceeds received by the Company.
• Future tranches are subject to conditions, including the effectiveness of a resale registration statement, which may not be met.

Risks

• Risk of significant dilution to existing shareholders due to the conversion feature of the notes.
• Risk that anticipated additional financing may not be completed on the described terms or at all.
• Risks related to the Company's obligations under the Purchase Agreement and related financing instruments, including repayment and prepayment obligations.
• Risk associated with default-related remedies available to Puritan Partners.
• Security interests in substantially all Company assets and specified subsidiary assets.

Future Outlook

The Company anticipates using this new facility to build out its regenerative bio-aesthetics platform and pursue other strategic opportunities. However, future tranches of financing are contingent on certain conditions, and there is a risk that additional financing may not be completed.

Management Comments

• "We're pleased to deepen our relationship with Puritan Partners through this new facility, which gives Longevity additional financial flexibility as we continue to build out our regenerative bio-aesthetics platform and pursue other strategic opportunities."
• Statement attributed to Janakiram Ajjarapu, Chairman and Chief Executive Officer.

Industry Context

StockSavvy.ai notes that securing financing through convertible notes, especially with asset backing, is a common strategy for companies in the biotechnology and aesthetics sectors that require capital for development and expansion but may face challenges accessing traditional debt or equity markets.

Stakeholder Impact

• Shareholders: Potential for significant dilution due to the conversion of notes into common stock.
• Creditors: Potential impact due to the senior secured nature of the notes, which encumber substantially all company assets.

Next Steps

• The Company intends to use the proceeds to build out its regenerative bio-aesthetics platform.
• The Company plans to pursue other strategic opportunities.
• Potential issuance of two additional notes, subject to conditions.

Key Dates

Recommendation

The financing provides necessary capital for operations and strategic initiatives, which is positive. However, the reliance on convertible debt with asset backing and significant dilution potential suggests financial challenges and uncertainty, warranting a cautious 'hold' stance until operational progress and financial health improve.

Keywords

convertible notes, securities purchase agreement, financing, regenerative bio-aesthetics, capital raise, asset-backed security, dilution